On November 4, 2025, Genprex, Inc. announced the European Patent Office's intention to grant a patent for Reqorsa® Gene Therapy combined with PD-1 antibodies for cancer treatment, expanding on existing patents in various countries. This development may enhance treatment options for lung cancer patients.